History

TruScreen’s development was led by leading medical academics from Sydney University who sought to establish objective technology that could improve on the conventional Pap test. They believed that it should be possible to distinguish between normal and abnormal tissue by measuring changes in physical properties, such as electrical potential.

TruScreen cervical screening

TruScreen’s development was led by leading medical academics from Sydney University.

Professor Coppleson, an international leader in colposcopy and cervical cancer, sought to establish objective technology that could improve on the conventional Pap test, which has limitations in population-based screening due to its subjective nature and its need of laboratory facilities and qualified personnel. Dr. Reid believed that it should be possible to distinguish between normal and abnormal tissue by measuring changes in physical properties, such as electrical potential.

After extensive and intensive R&D, the TruScreen ‘Opto Electrical’ Technology for the detection of cancerous cells was developed. The TruScreen Cervical Cancer Screening System is built on this technology and comprises a unique medical device, algorithm technology and processes designed to detect the presence, at the time of screening, of pre-cancerous and cancerous tissue on the cervix.

Following the restructuring of the business, TruScreen Pty Ltd, a subsidiary company of TruScreen Ltd (NZ), was formed in October 2013 to hold all TruScreen assets, including IP, and to act as the operations heart of the TruScreen business. The board and executive team combine experience and commercial ideas and strategies which we believe are both essential to and sufficient for the success of TruScreen globally.

In 2016, the TruScreen2 second-generation device was launched. This encapsulates world-class medical technology and contains many new and unique features including a massively increased processing capacity and faster processing, improved performance and improved user experience.

The TruScreen technology is at the forefront of the development of objective opto-electric tissue differentiation and it enjoys significant intellectual property protection.